The ACAT inhibitor avasimibe increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1738, Issue 1-3, 2005, Pages 10-18

  Burnett, John R ^a   Telford, Dawn E ^b   Barrett, P Hugh R ^a   Huff, Murray W ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

ACAT inhibitor; Avasimibe; Compartmental model; Tracer kinetic; Triglyceride rich lipoprotein

Indexed keywords

APOLIPOPROTEIN B; AVASIMIBE; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; LIPOPROTEIN; RETINOL; RETINOL PALMITATE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

AMINO ACID ANALYSIS; AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BODY FAT; CHOLESTEROL ESTERIFICATION; COMPARTMENT MODEL; CONCENTRATION (PARAMETERS); DIET RESTRICTION; DRUG EFFECT; ENZYME INHIBITION; INTESTINE; INTESTINE ABSORPTION; KINETICS; LIPOPROTEIN METABOLISM; METABOLIC CLEARANCE RATE; METABOLIC INHIBITION; MINIPIG; MODULATION; NONHUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN SECRETION; TRIACYLGLYCEROL BLOOD LEVEL;

ACETATES; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; INTESTINE, SMALL; KINETICS; LIPIDS; LIPOPROTEINS; LIVER; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; POSTPRANDIAL PERIOD; STEROL O-ACYLTRANSFERASE; SULFONIC ACIDS; SWINE; SWINE, MINIATURE; TRIGLYCERIDES;

ANIMALIA;

EID: 31044443222     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2005.11.010     Document Type: Article

References (66)

1. K.E. Suckling, and E.F. Strange Role of acyl-CoA:cholesterol acyltransferase in cellular cholesterol metabolism J. Lipid Res. 26 1985 647 671
2. T.Y. Chang, C.C.Y. Chang, and D. Cheng Acyl-coenzyme A:cholesterol acyltransferase Annu. Rev. Biochem. 66 1997 613 638
3. T.Y. Chang, C.C.Y. Chang, and K.M. Cadigan The structure of acyl coenzyme A-cholesterol acyltransferase and its potential relevance to atherosclerosis Trends Cardiovasc. Med. 4 1994 223 230
4. L.L. Rudel, and G.S. Shelness Cholesterol esters and atherosclerosis-A game of ACAT and mouse Nat. Med. 6 2000 1313 1314
5. J.R. Burnett, L.J. Wilcox, and M.W. Huff Acyl coenzyme A: cholesterol acyltransferase inhibition and hepatic apolipoprotein B secretion Clin. Chim. Acta 286 1999 231 242
6. S. Cases, S. Novak, Y.W. Zheng, H.M. Myers, S.R. Lear, E. Sande, C.B. Welch, A.J. Lusis, T.A. Spencer, B.R. Krause, S.K. Erickson, and R.V. Farese Jr. ACAT-2, a second mammalian acyl CoA: cholesterol acyltransferase: its cloning, expression, and characterization J. Biol. Chem. 273 1998 26755 26771
7. R.A. Anderson, C. Joyce, M. Davis, J.W. Reagan, M. Clark, G.S. Shelness, and L.L. Rudel Identification of a form of acyl-CoA:cholesterol acyltransferase specific to liver and intestine in nonhuman primates J. Biol. Chem. 273 1998 26747 26754
8. P. Oelkers, A. Behari, D. Cromley, J.T. Billheimer, and S.L. Sturley Characterization of two human genes encoding acyl coenzyme A-cholesterol acyltransferase related enzymes J. Biol. Chem. 273 1998 26765 26778
9. P. Parini, M. Davis, A.T. Lada, S.K. Erickson, T.L. Wright, U. Gustafsson, S. Sahlin, C. Einarsson, M. Eriksson, B. Angelin, H. Tomoda, S. Omura, M.C. Willingham, and L.L. Rudel ACAT2 is localized to hepatocytes and is the major cholesterol-esterifying enzyme in human liver Circulation 110 2004 2017 2023
10. L.L. Rudel, R.G. Lee, and T.L. Cockman Acyl coenzyme A: cholesterol acyltransferase types 1 and 2: structure and function in atherosclerosis Curr. Opin. Lipidol. 12 2001 121 127
11. T.Y. Chang, C.C.Y. Chang, S. Lin, C. Yu, B.L. Li, and A. Miyazaki Roles of acyl-coenzyme A: cholesterol acyltransferase-1 and -2 Curr. Opin. Lipidol. 12 2001 289 296
12. E.L. Willner, B. Tow, K.K. Buhman, M. Wilson, D.A. Sanan, L.L. Rudel, and R.V. Farese Jr. Deficiency of acyl CoA:cholesterol acyltransferase 2 prevents atherosclerosis in apolipoprotein E-deficient mice Proc. Natl. Acad. Sci. U. S. A. 100 2003 1262 1267
13. M. Accad, S.J. Smith, D.L. Newland, D.A. Sanan, L.E. King Jr., M.F. Linton, S. Fazio, and R.V. Farese Jr. Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA: cholesterol acyltransferase J. Clin. Invest. 105 2000 711 719
14. H.T. Lee, W.H. Roark, J.A. Picard, D.R. Sliskovic, B.D. Roth, R.L. Stanfield, K.L. Hamahele, R.F. Bousley, and B.R. Krause Inhibitors of acyl-CoA: cholesterol O-acyltransferase (ACAT) as hypocholesterolemic agents: synthesis and structure-activity relationships of novel series of sulfonamides, acylphosphonamides and acylphosphoramidates Biooorg. Med. Chem. Lett. 3 1998 289 294
15. H.T. Lee, D.R. Sliskovic, J.A. Picard, B.D. Roth, W. Wieranga, J.L. Hicks, R.F. Bousley, K.L. Hamelehle, R. Homan, C. Speyer, R.L. Stanfield, and B.R. Krause Inhibitors of acyl-CoA:cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering in animals fed noncholesterol-supplemented diets J. Med. Chem. 39 1996 5031 5034
16. J.R. Burnett, and M.W. Huff Avasimibe (Pfizer) Curr. Opin. Investig. Drugs 3 2002 1328 1333
17. R. Ramharack, M.A. Spahr, C.S. Sekerke, R.L. Stanfield, R.F. Bousley, H.T. Lee, and B.R. Krause CI-1011 lowers lipoprotein(a) and plasma cholesterol concentrations in chow-fed cynomolgus monkeys Atherosclerosis 136 1998 79 87
18. B.R. Krause, and B.J. Auerbach ACAT inhibition by CI-1011 lowers plasma triglycerides in rats by enhancing the clearance of VLDL Atherosclerosis 134 1997 128 (Abstract)
19. R.J. Nicolosi, T.A. Wilson, and B.R. Krause The ACAT inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters Atherosclerosis 137 1998 77 85
20. T.M.A. Bocan, S.B. Mueller, E.Q. Brown, P. Lee, M.J. Bocan, T. Rea, and M.E. Pape HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit Atherosclerosis 139 1998 21 30
21. D.J.M. Delsing, E.H. Offerman, W. van Duyvenvoorde, H. van der Boom, E.C.M. de Wit, M.J.J. Gijbels, A. van der Laarse, J.W. Jukema, L.M. Havekes, and H.M.G. Princen Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in apoE*3-Leiden mice Circulation 103 2001 1778 1786
22. T.M.A. Bocan, B.R. Krause, W.S. Rosebury, S.B. Mueller, X. Lu, C. Dagle, T. Major, C. Lathia, and H. Lee The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits Arterioscler., Thromb., Vasc. Biol. 20 2000 70 79
23. T.M.A. Bocan, B.R. Krause, W.S. Rosebury, X. Lu, C. Dagle, S.B. Mueller, B. Auerbach, and D.R. Sliskovic The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression Atherosclerosis 157 2001 97 105
24. L.J. Wilcox, P.H.R. Barrett, R.S. Newton, and M.W. Huff ApoB100 secretion in HepG2 cells is decreased by the ACAT inhibitor CI-1011: an effect associated with enhanced intracellular degradation of apoB Arterioscler., Thromb., Vasc. Biol. 19 1999 939 949
25. C. Taghibiglou, S.C. van Iderstine, A. Kulinski, D. Rudy, and K. Adeli Intracellular mechanisms mediating the inhibition of apoB-containing lipoprotein synthesis and secretion in HepG2 cells by avasimibe (CI-1011), a novel acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor Biochem. Pharmacol. 63 2003 349 360
26. H.B. Rubins, S.J. Robins, D. Collins, C.L. Fye, J.W. Anderson, M.B. Elam, F.H. Faas, E. Linares, E.F. Schaefer, G. Schectman, T.J. Wilt, and J. Wittes Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group N. Engl. J. Med. 341 1999 410 418
27. W. Insull Jr., M. Koren, J. Davignon, D. Sprecher, H. Schrott, L.M. Keilson, A.S. Brown, C.A. Dujovne, M.H. Davidson, R. McLain, and T. Heinonen Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, in patients with combined hyperlipidemia Atherosclerosis 157 2001 137 144
28. F.J. Raal, A.D. Marais, E. Klepack, J. Lovalvo, R. McLain, and T. Heinonen Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia Atherosclerosis 171 2003 273 279
29. M.W. Huff, D.E. Telford, P.H.R. Barrett, J.T. Billheimer, and P.J. Gillies Inhibition of hepatic ACAT decreases apoB secretion in miniature pigs fed a cholesterol-free diet Arterioscler. Thromb. 14 1994 1498 1508
30. J.R. Burnett, L.J. Wilcox, D.E. Telford, S.J. Kleinstiver, P.H.R. Barrett, and M.W. Huff Inhibition of cholesterol esterification by DuP 128 decreases hepatic apolipoprotein B secretion in vivo: effect of dietary fat and cholesterol Biochim. Biophys. Acta 1393 1998 63 79
31. J.R. Burnett, L.J. Wilcox, D.E. Telford, S.J. Kleinstiver, P.H.R. Barrett, R.S. Newton, and M.W. Huff Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs J. Lipid Res. 40 1999 1317 1327
32. J.R. Burnett, P.H.R. Barrett, P. Vicini, D.B. Miller, D.E. Telford, S.J. Kleinstiver, and M.W. Huff The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs Arterioscler., Thromb., Vasc. Biol. 18 1998 1906 1914
33. K.G. Parhofer, P.H.R. Barrett, and P. Schwandt Atorvastatin improves postprandial lipoprotein metabolism in normolipidemic subjects J. Clin. Endocrinol. Metab. 85 2000 4224 4230
34. S. Boquist, F. Karpe, K. Danell-Toverud, and A. Hamsten Effects of atorvastatin on postprandial plasma lipoproteins in postinfarction patients with combined hyperlipidaemia Atherosclerosis 162 2002 163 170
35. N.M. Borradaile, L.E. de Dreu, L.J. Wilcox, Y.Y. Edwards, and M.W. Huff Soya phyoestrogens, genistein and daidzein, decrease apolipoprotein B secretion from HepG2 cells through multiple mechanisms Biochem. J. 366 2002 531 539
36. J.R. Burnett, L.J. Wilcox, D.E. Telford, S.J. Kleinstiver, P.H.R. Barrett, R.S. Newton, and M.W. Huff Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apoB production in miniature pigs Arterioscler., Thromb., Vasc. Biol. 17 1997 2589 2600
37. M.A.K. Markwell, S.M. Haas, L.L. Bieber, and N.E. Tolbert A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples Anal. Biochem. 87 1978 206 210
38. J.S. Cohn Postprandial lipid metabolism Curr. Opin. Lipidol. 5 1994 185 190
39. F. Karpe Postprandial lipoprotein metabolism and atherosclerosis J. Intern. Med. 246 1999 341 355
40. M.M. Hussain, T.L. Innerarity, W.J. Brecht, and R.W. Mahley Chylomicron metabolism in normal, cholesterol-fed, and Watanabe heritable hyperlipidemic rabbits. Saturation of the sequestration step of the remnant clearance pathway J. Biol. Chem. 270 1995 8578 8587
41. Z. Ji, S. Fazio, Y. Lee, and R.W. Mahley Secretion-capture role for apolipoprotein E in remnant lipoprotein metabolism involving cell surface heparan sulfate proteoglycans J. Biol. Chem. 269 1994 2764 2772
42. Z. Ji, W.J. Brecht, R.D. Miranda, M.M. Hussain, T.L. Innerarity, and R.W. Mahley Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells J. Biol. Chem. 268 1993 10160 10167
43. Z. Ji, D.A. Sanan, and R.W. Mahley Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans J. Lipid Res. 36 1995 583 592
44. A. Niemeier, M. Gåfvels, J. Heeren, N. Meyer, B. Angelin, and U. Beisiegel VLDL receptor mediates the uptake of human chylomicron remnants in vitro J. Lipid Res. 37 1996 1733 1742
45. S. Takahashi, Y. Kawarabayasi, T. Nakai, J. Sakai, and T. Yammamoto Rabbit very low density lipoprotein receptor-like protein with distinct ligand specificity Proc. Natl. Acad. Sci. U. S. A. 89 1992 9252 9256
46. J. Björkegren, F. Karpe, R. Milne, and A. Hamsten Differences in apolipoprotein and lipid composition between human chylomicron remnants and very low density lipoproteins isolated from fasting and postprandial plasma J. Lipid Res. 39 1998 1412 1420
47. V. Brown, and M.L. Baginsky Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein Biochim. Biophys. Acta 46 1972 375 382
48. P.K.J. Kinnunen, and C. Ehnholm Effect of serum and C-apoproteins from very low density lipoproteins on human post-heparin plasma hepatic lipase FEBS Lett. 65 1976 354 357
49. F. Shelbourne, J. Hanks, W. Meyers, and S.A. Quarfordt Effect of apoproteins on hepatic uptake of triglyceride emulsions in the rat J. Clin. Invest. 65 1980 652 658
50. E. Windler, and R.J. Havel Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver J. Lipid Res. 26 1985 556 563
51. K. Aalto-Setälä, E.A. Fisher, X. Chen, T. Chajek-Shaul, T. Hayek, R. Zechner, R. Walsh, R. Ramakrishnan, H.N. Ginsberg, and J.L. Breslow Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apoCIII and reduced apoE on the particles J. Clin. Invest. 90 1992 1889 1900
52. H.V. de Silva, S.J. Lauer, J. Wang, W.S. Simonet, K.H. Weisgraber, and R.W. Mahley Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E J. Biol. Chem. 269 1994 2324 2335
53. N. Maeda, H. Li, D. Lee, P. Oliver, S.H. Quarfordt, and J. Osada Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia J. Biol. Chem. 269 1994 23610 23616
54. A.J. Evans, B.M. Wolfe, W.L.P. Strong, and M.W. Huff Reduced lipolysis of large apoE-poor very-low-density lipoprotein subfractions from Type IV hypertriglyceridemic subjects in vitro and in vivo Metabolism 42 1993 105 115
55. S.H. Gianturco, F.B. Brown, A.M. Gotto Jr., and W.A. Bradley Receptor-mediated uptake of hypertriglyceridemic very low density lipoproteins by normal human fibroblasts J. Lipid Res. 23 1982 984 993
56. S. Ishibashi, J. Herz, N. Maeda, J.L. Goldstein, and M.S. Brown The two-receptor model of lipoprotein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins Proc. Natl. Acad. Sci. U. S. A. 91 1994 4431 4435
57. S. Ishibashi, S. Perrey, Z. Chen, J. Osuga, M. Shimada, K. Ohashi, K. Harada, Y. Yazaki, and N. Yamada Role of the low density lipoprotein (LDL) receptor pathway in the metabolism of chylomicron remnants. A quantitative study in knockout mice lacking the LDL receptor, apolipoprotein E, or both J. Biol. Chem. 271 1996 22422 22427
58. J.S. Cohn, J.R. McNamara, S.D. Cohn, J.M. Ordovas, and E.J. Schaefer Plasma apolipoprotein changes in the triglyceride-rich lipoprotein fraction of human subjects fed a fat-rich meal J. Lipid Res. 29 1988 925 936
59. F. Karpe, G. Steiner, T. Olivecrona, L.A. Carlson, and A. Hamsten Metabolism of triglyceride-rich lipoproteins during alimentary lipemia J. Clin. Invest. 91 1993 748 759
60. B.O. Schneeman, L. Kotite, K.M. Todd, and R.J. Havel Relationship between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to fat-containing meal in normolipidemic humans Proc. Natl. Acad. Sci. U. S. A. 90 1993 2069 2073
61. J.D. Brunzell, W.R. Hazzard, D. Porte Jr., and E.L. Bierman Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man J. Clin. Invest. 52 1973 1578 1585
62. S.J. Robins, J.M. Fasulo, V.F. Robins, and G.M. Patton Response of serum triglycerides of endogenous origin to the administration of triglyceride-rich lipid particles Am. J. Physiol. 257 1989 E860 E865
63. F. Karpe, and M. Hultin Endogenous triglyceride-rich lipoproteins accumulate in rat plasma when competing with a chylomicron-like triglyceride emulsion for a common lipolytic pathway J. Lipid Res. 36 1995 1557 1566
64. J. Björkegren, C.J. Packard, A. Hamsten, D. Bedford, M. Caslake, L. Foster, J. Shepherd, P. Stewart, and F. Karpe Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a chylomicron-like triglyceride emulsion reflects competition for a common lipolytic pathway J. Lipid Res. 37 1996 76 86
65. N. Le, P.M. Coates, P.R. Gallagher, and J.A. Cortner Kinetics of retinyl esters during postprandial lipemia in man: a compartmental model Metabolism 46 1997 584 594
66. J. Tardif, J. Grégoire, P.L. L'Allier, T.J. Anderson, O. Bertrand, F. Reeves, L.M. Title, F. Alfonso, E. Schampaert, A. Hassan, R. McLain, M.L. Pressler, R. Ibrahim, J. Lespérance, J. Blue, T. Heinonen, J. Rodés-Cabau for the Avasimibe and Progression of Lesions on UltraSound (A-PLUS) Investigators Effects of acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions Circulation 110 2004 3372 3377